Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT04449874
Official study title

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Study summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedGDC-6036 and Atezolizumab

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 28, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?63 U.S. locations

Locations may change over time.

Who runs it?Genentech, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Genentech, Inc.
Interventions being studied
Drug: GDC-6036; Drug: Atezolizumab; Drug: Cetuximab; Drug: Bevacizumab; Drug: Erlotinib; Drug: GDC-1971; Drug: Inavolisib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
  • Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
  • Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
Reasons someone may not be able to joinExclusion criteria
  • Active brain metastases.
  • Malabsorption or other condition that interferes with enteral absorption.
  • Clinically significant cardiovascular dysfunction or liver disease.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope Comprehensive Cancer CenterDuarte, California
  • UCSD Moores Cancer CenterLa Jolla, California
  • Chao Family Comprehensive Cancer Center UCIOrange, California
  • Yale Cancer CenterNew Haven, Connecticut
  • Florida Cancer Specialists - SarasotaSarasota, Florida
  • Dana Farber Cancer InstituteBoston, Massachusetts
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • University of OklahomaOklahoma City, Oklahoma
  • UPMC - Hillman Cancer CenterPittsburgh, Pennsylvania
  • Slade Health Inward goodsMount Kuring-Gai, New South Wales
  • Peter MacCallum Cancer CenterMelbourne, Victoria
  • Alfred HealthMelbourne, Victoria

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2026. Always confirm current availability with the study team.

View original record ↗